Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 253

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Irritable Bowel Syndrome–Type Symptoms in Patients With Inflammatory Bowel Disease: A Real Association or Reflection of Occult Inflammation?

Open access
Keohane, John, O'Mahony, Caitlin, O'Mahony, Liam, O'Mahony, Siobhan, Quigley, Eamonn M, Shanahan, Fergus·2010·American Journal of Gastroenterology
DOI 10.1038/ajg.2010.156
Open this paper in CoChat — free account

Abstract

OBJECTIVES: Do gastrointestinal symptoms in patients with inflammatory bowel disease (IBD) in apparent remission reflect the coexistence of irritable bowel syndrome (IBS) or subclinical inflammation? The aims of this study were as follows: (i) to prospectively determine the prevalence of IBS symptoms in IBD patients in remission; and (ii) to determine whether IBS symptoms correlate with levels of fecal calprotectin. METHODS: Remission was defined by physician assessment: Crohn's disease (CD) activity index <or=150 and ulcerative colitis disease activity index <or=3, and serum C-reactive protein <10, while off corticosteroids or biologics. Quality of life (QOL) (by inflammatory bowel disease questionnaire), the hospital anxiety and depression scale (HAD), and fecal calprotectin were measured. RESULTS: Rome II criteria for IBS were fulfilled in 37/62 (59.7%) of CD patients and by 17/44 (38.6%) of those with ulcerative colitis (UC). However, fecal calprotectin was significantly elevated above the upper limit of normal in both IBD patient groups, indicating the presence of occult inflammation. Furthermore, calprotectin levels were significantly higher in CD and UC patients with criteria for IBS than in those without IBS-type symptoms. QOL scores were lower and HAD scores higher among UC patients with IBS symptoms in comparison to those who did not have IBS symptoms. CONCLUSIONS: IBS-like symptoms are common in patients with IBD who are thought to be in clinical remission, but abnormal calprotectin levels suggest that the mechanism in most cases is likely to be occult inflammation rather than coexistent IBS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ajg.2010.156

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 32

  1. Minderhoud, 2004, IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior., Dig Dis Sci, 49, 469, 10.1023/B:DDAS.0000020506.84248.f9 · DOI
  2. Bernstein, 2008, Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases., Gut, 57, 1185, 10.1136/gut.2007.122143 · DOI · Paper page
  3. Hungin, 2003, The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects., Aliment Pharmacol Ther, 17, 643, 10.1046/j.1365-2036.2003.01456.x · DOI · Paper page
  4. Longobardi, 2003, Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey., Am J Gastroenterol, 98, 1064
  5. Rogala, 2008, Population-based controlled study of social support, self-perceived stress, activity and work issues, and access to health care in inflammatory bowel disease., Inflamm Bowel Dis, 14, 526, 10.1002/ibd.20353 · DOI
  6. Bernstein, 2001, The relationship between inflammatory bowel disease and socioeconomic variables., Am J Gastroenterol, 96, 2117, 10.1111/j.1572-0241.2001.03946.x · DOI
  7. Creed, 2001, Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome., Ann Intern Med, 134, 860, 10.7326/0003-4819-134-9_Part_2-200105011-00010 · DOI
  8. Wells, 1997, Clinical economics review: irritable bowel syndrome., Aliment Pharmacol Ther, 11, 1019, 10.1046/j.1365-2036.1997.00262.x · DOI
  9. Best, 1976, Development of a Crohns disease activity index. National Cooperative Crohns Disease Study., Gastroenterology, 70, 439, 10.1016/S0016-5085(76)80163-1 · DOI
  10. Walmsley, 1998, A simple clinical colitis activity index., Gut, 43, 29, 10.1136/gut.43.1.29 · DOI · Paper page
  11. Guyatt, 1989, A new measure of health status for clinical trials in inflammatory bowel disease., Gastroenterology, 96, 804, 10.1016/S0016-5085(89)80080-0 · DOI · Paper page
  12. Fagerhol, 2000, Calprotectin, a faecal marker of organic gastrointestinal abnormality., Lancet, 356, 1783, 10.1016/S0140-6736(00)03224-4 · DOI
  13. Tibble, 2002, Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease., Gastroenterology, 123, 450, 10.1053/gast.2002.34755 · DOI · Paper page
  14. Tibble, 2000, A simple method for assessing intestinal inflammation in Crohns disease., Gut, 47, 506, 10.1136/gut.47.4.506 · DOI
  15. Tibble, 2000, Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease., Gastroenterology, 119, 15, 10.1053/gast.2000.8523 · DOI · Paper page
  16. Satsangi, 2005, The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications., Gut, 55, 749, 10.1136/gut.2005.082909 · DOI · Paper page
  17. Vermeire, 2006, Laboratory markers in IBD: useful, magic, or unnecessary toys?, Gut, 55, 426, 10.1136/gut.2005.069476 · DOI · Paper page
  18. Sutherland, 2008, Review of fecal biomarkers in inflammatory bowel disease., Dis Colon Rectum, 51, 1283, 10.1007/s10350-008-9310-8 · DOI
  19. DHaens, 2007, A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis., Gastroenterology, 132, 763, 10.1053/j.gastro.2006.12.038 · DOI · Paper page
  20. Dinan, 2006, Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?, Gastroenterology, 130, 304, 10.1053/j.gastro.2005.11.033 · DOI · Paper page
  21. Liebregts, 2007, Immune activation in patients with irritable bowel syndrome., Gastroenterology, 132, 913, 10.1053/j.gastro.2007.01.046 · DOI · Paper page
  22. Shanahan, 1998, Enteric neuropathophysiology and inflammatory bowel disease., Neurogastroenterol Motil, 10, 185, 10.1046/j.1365-2982.1998.00104.x · DOI
  23. Mawe, 2004, Changes in enteric neural circuitry and smooth muscle in the inflamed and infected gut., Neurogastroenterol Motil, 16, 133, 10.1111/j.1743-3150.2004.00489.x · DOI
  24. Otten, 2008, Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome., Clin Chem Lab Med, 46, 1275, 10.1515/CCLM.2008.361 · DOI
  25. Schoepfer, 2008, Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies., Inflamm Bowel Dis, 14, 32, 10.1002/ibd.20275 · DOI · Paper page
  26. Langhorst, 2008, Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices., Am J Gastroenterol, 103, 162, 10.1111/j.1572-0241.2007.01556.x · DOI · Paper page
  27. Desmond, 2008, Crohns disease: factors associated with exposure to high levels of diagnostic radiation., Gut, 57, 1524, 10.1136/gut.2008.151415 · DOI
  28. OLeary, 2002, Celiac disease and irritable bowel-type symptoms., Am J Gastroenterol, 97, 1463, 10.1111/j.1572-0241.2002.05690.x · DOI
  29. OLeary, 2003, Small bowel bacterial overgrowth, coeliac disease, and IBS: what are the associations?, Am J Gastroenterol, 98, 720, 10.1111/j.1572-0241.2003.07395.x · DOI
  30. Quigley, 2005, Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases?, Chin J Dig Dis, 6, 122, 10.1111/j.1443-9573.2005.00202.x · DOI
  31. Quigley, 2009, The language of medicine: words as servants and scoundrals., Clin Med, 9, 131, 10.7861/clinmedicine.9-2-131 · DOI
  32. Grover, 2009, The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome., Clin Gastroenterol Hepatol, 7, 48, 10.1016/j.cgh.2008.08.032 · DOI

Cited by

Metadata

Authors
Keohane, J., O'Mahony, C., O'Mahony, L., O'Mahony, S., Quigley, E. M., & Shanahan, F.
Venue
American Journal of Gastroenterology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2010-08
Volume
105
Issue
8
Pages
1789-1794
ISSN
0002-9270 (ISSN-L)
DOI
10.1038/ajg.2010.156
OpenAlex
W1979871033
Cited by
253
References
8
FWCI
12.57
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.